Tuberculosis Foundation selects Core Research Scientists

March 19, 2000

In an initial step towards the development of a new vaccine to prevent tuberculosis, the Sequella Global Tuberculosis Foundation has named 13 researchers to the Core Scientist Program of its Tuberculosis Vaccine Collaboration (TBVC) program. Acting as a focused research team, these core scientists will help to guide the Foundation as it supports new and innovative tuberculosis vaccine development.

"What we are trying to do in the Core Scientist Program is to accelerate the transition of experimental vaccines from the research bench to the clinic. The three major areas addressed by this program are clinical trial site development, new tools for vaccine assessment in clinical trials, and research supporting the eventual clinical evaluation of candidate tuberculosis vaccines," says Carol Nacy, Ph.D., President of the Foundation. "Our goal is not just the research, but an actual vaccine."

Once thought to be under control and nearly eradicated in industrialized countries, tuberculosis continues to be a threat in all countries because of increasing drug resistance. It is estimated that nearly a third of the world's population, approximately 2 billion people, are infected with Mycobacterium tuberculosis, the bacterium that causes the disease. About 10% of these individuals will develop active tuberculosis disease within their lifetime. The antibiotics and the vaccine currently used to treat and prevent this disease are antiquated and have limited effectiveness.

The Core Scientists Program is the first step in the Foundation's TBVC, an international program designed to coordinate and facilitate the development of a vaccine. The scientists represent a variety of scientific, engineering and public health disciplines that are necessary to create a successful vaccine.

Later this year the Foundation will begin accepting investigator-initiated grant applications in its Vaccine Innovation Program, designed to fund novel tuberculosis vaccine research.
Founded in 1997, the Sequella Global Tuberculosis Foundation is a non-profit organization devoted to providing resources, facilities and expertise to assist tuberculosis researchers across the world to move their discoveries in basic science through the laboratory, into the clinic and out to health care workers. It is funded by a number of corporate and philanthropic sources including a generous grant from the Bill and Melinda Gates Foundation.

The TBVC core scientists are:

* Marcel A. Behr, MD, Assistant Professor, McGill University Health Centre, Montreal
* William Bishai, MD, Ph.D., Associate Professor of International Health and Medicine, Johns Hopkins University, Baltimore
* Barry R. Bloom, Ph.D., Dean, Harvard School of Public Health
* Anne S. De Groot, MD, CEO, EpiVax, Inc., Providence, Rhode Island
* Wafaa El Sadr, MD, MPH, Professor of Clinical Medicine, Columbia University, New York
* William R. Jacobs, Jr., Ph.D., Professor, The Albert Einstein College of Medicine of Yeshiva University, New York
* Gilla Kaplan, Ph.D., Associate Professor, The Rockefeller University, New York
* Douglas B. Lowrie, Ph.D., St. Georges Hospital, London
* John D. McKinney, Ph.D., Assistant Professor, The Rockefeller University, New York
* Boris V. Nikonenko, Ph.D., Sequella, Inc., Rockville, Maryland
* Erwin Schurr, Ph.D., Associate Professor McGill Centre for the Study of Host Resistance at the McGill University Health Centre Research Institute, Montreal
* David R. Sherman, Ph.D., Assistant Professor, University of Washington School of Public Health and Community Medicine, Seattle
* Zena Stein, M.A., MBBCh, Professor, Columbia University, New York


Related Vaccine Articles from Brightsurf:

Who should get the COVID-19 vaccine first?
Nineteen global health experts from around the world have proposed a new, three-phase plan for vaccine distribution -- called the Fair Priority Model -- which aims to reduce premature deaths and other irreversible health consequences from COVID-19.

Breakthrough with cancer vaccine
Scientists have developed a new cancer vaccine with the potential to activate the body's immune system to fight a range of cancers, including leukaemia, breast cancer, lung cancer and pancreatic cancers.

How to improve the pneumococcus vaccine
Pneumococcus kills 1 million children annually according to the World Health Organization.

US inroads to better Ebola vaccine
As the world focuses on finding a COVID-19 vaccine, research continues on other potentially catastrophic pandemic diseases, including Ebola and Marburg viruses.

Successful MERS vaccine in mice may hold promise for COVID-19 vaccine
In a new study, published April 7 in mBio, researchers from the University of Iowa and the University of Georgia demonstrate that a new vaccine fully protects mice against a lethal dose of MERS, a close cousin of COVID-19.

Coronavirus Vaccine: Where are we and what's next? (video)
You might have heard that COVID-19 vaccine trials are underway in Seattle.

Why isn't there a vaccine for staph?
A study from Washington University School of Medicine in St.

Exposing vaccine hesitant to real-life pain of diseases makes them more pro-vaccine
New research from Brigham Young University professors finds there is a better way to help increase support for vaccinations: Expose people to the pain and suffering caused by vaccine-preventable diseases instead of trying to combat people with vaccine facts.

Lifetime flu vaccine?
Another year, another flu vaccine because so far scientists haven't managed to make a vaccine that protects against all strains of flu.

On the horizon: An acne vaccine
A new study published in the Journal of Investigative Dermatology reports important steps that have been taken towards the development of an acne vaccine.

Read More: Vaccine News and Vaccine Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to